In This Section
Amgen has built an organization distinguished by world-class scientists with a talent for applying novel approaches to treat disease. Our R&D strategy aims to align and engage our talent, prioritize investments, and seize scientific opportunities.
Amgen has created a robust and differentiated pipeline, leveraging state-of-the-art science to create medicines for serious illnesses.
From studying DNA in the lab to working with patients in clinical trials, Amgen scientists are pioneering new approaches to understanding human biology and making innovative medicines to treat disease. Join leaders at Amgen and beyond for in-depth discussions of the latest science and discoveries in our podcasts developed in collaboration with The Scientist.
The Scientific Advisory Board provides external scientific review of R&D activities and assists management in its responsibility to make significant scientific judgments related to R&D activities and portfolio.
Among the most important steps in the long and careful process to develop new therapies are clinical trials, where people volunteer to receive an experimental new drug or procedure and be observed for its effects.
At Amgen, we continually invest in our manufacturing to strengthen our industry-leading capabilities and extend our global reach. Our commitment is to ensure that all our medicines are available for "every patient, every time."
Biosimilars offer the potential to increase patient access to vital medicines. Amgen is well positioned to leverage its more than 35 years of experience in biotechnology to create high-quality biosimilars and reliably supply them to patients worldwide.
At Amgen, we are deeply committed to our mission to serve patients. This goes beyond developing, manufacturing and delivering vital medicines.